Genesis IBRC India Past Earnings Performance
Past criteria checks 0/6
Genesis IBRC India's earnings have been declining at an average annual rate of -73.4%, while the Biotechs industry saw earnings growing at 9.7% annually. Revenues have been growing at an average rate of 103.3% per year.
Key information
-73.4%
Earnings growth rate
-73.2%
EPS growth rate
| Biotechs Industry Growth | 5.1% |
| Revenue growth rate | 103.3% |
| Return on equity | -1.9% |
| Net Margin | -4.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Genesis IBRC India makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 37 | -2 | 0 | 0 |
| 30 Jun 24 | 0 | -38 | 0 | 0 |
| 31 Mar 24 | 0 | -38 | 0 | 0 |
| 31 Dec 23 | 0 | -2 | 1 | 0 |
| 30 Sep 23 | 0 | -2 | 1 | 0 |
| 30 Jun 23 | 0 | -2 | 1 | 0 |
| 31 Mar 23 | 0 | -1 | 1 | 0 |
| 31 Dec 22 | 0 | -1 | 0 | 0 |
| 30 Sep 22 | 0 | -1 | 0 | 0 |
| 30 Jun 22 | 0 | -1 | 0 | 0 |
| 31 Mar 22 | 0 | -1 | 0 | 0 |
| 31 Dec 21 | 0 | -1 | 0 | 0 |
| 30 Sep 21 | 0 | -1 | 1 | 0 |
| 30 Jun 21 | 0 | -1 | 1 | 0 |
| 31 Mar 21 | 0 | -1 | 0 | 0 |
| 31 Dec 20 | 0 | -1 | 0 | 0 |
| 30 Sep 20 | 0 | -1 | 0 | 0 |
| 30 Jun 20 | 0 | -1 | 0 | 0 |
| 31 Mar 20 | 0 | -1 | 0 | 0 |
| 31 Dec 19 | 1 | 0 | 0 | 0 |
| 30 Sep 19 | 1 | 0 | 0 | 0 |
| 30 Jun 19 | 1 | -1 | 0 | 0 |
| 31 Mar 19 | 1 | -1 | 0 | 0 |
| 30 Jun 18 | 43 | -1 | 8 | 0 |
| 31 Mar 18 | 43 | 0 | 8 | 0 |
| 30 Jun 17 | 0 | 0 | 0 | 0 |
| 31 Mar 17 | 0 | 0 | 0 | 0 |
| 31 Dec 16 | 0 | 3 | 0 | 0 |
| 30 Sep 16 | 0 | 3 | 0 | 0 |
| 30 Jun 16 | 0 | 3 | 0 | 0 |
| 31 Mar 16 | 0 | 3 | 0 | 0 |
| 31 Dec 15 | 0 | -3 | 0 | 0 |
| 30 Sep 15 | 5 | -3 | 0 | 0 |
| 30 Jun 15 | 6 | -3 | 0 | 0 |
| 31 Mar 15 | 8 | -4 | 0 | 0 |
| 31 Dec 14 | 9 | -1 | 1 | 0 |
| 30 Sep 14 | 5 | -2 | 1 | 0 |
| 30 Jun 14 | 4 | -3 | 1 | 0 |
| 31 Mar 14 | 4 | -3 | 1 | 0 |
| 31 Dec 13 | 3 | -3 | 1 | 0 |
Quality Earnings: 514336 is currently unprofitable.
Growing Profit Margin: 514336 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 514336 is unprofitable, and losses have increased over the past 5 years at a rate of 73.4% per year.
Accelerating Growth: Unable to compare 514336's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 514336 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3.4%).
Return on Equity
High ROE: 514336 has a negative Return on Equity (-1.87%), as it is currently unprofitable.